BioInformant

Your Global Leader in Stem Cell Market Research

Home » cynata therapeutics » Page 2

Parkinson’s Disease Clinical Trial to Launch in Japan | iPS Cell Trial

By Leave a Comment

Japan will continue its dominance with iPS cell clinical trials with the launch of a physician-lead trial for Parkinson’s disease. In its July 2018 press announcement, Kyoto University announced that its University Hospital and the Center for iPS Cell Research and Application (CiRA) will launch the world’s first clinical trial for Parkinson’s disease to utilize an induced pluripotent stem cell (iPS cell) derived therapeutic product.

Existing iPS Cell Trials

This newest iPS cell trial represents only the third iPS cell trial to be undertaken worldwide. The other existing iPS cell trials are being conducted by the RIKEN Center for Developmental Biology (CDC) and Cynata Therapeutics (ASX:CYP), respectively. [Read more…]

Cymerus™ MSC treatment leads to improved recovery of cardiac function in preclinical heart attack study

By Leave a Comment

Melbourne, Australia; 31 July 2018: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce positive efficacy data from a study of its Cymerus mesenchymal stem cells (MSCs) in a preclinical heart attack model. [Read more…]

Dr. Paul Wotton on the Future of Cynata Therapeutics’ Novel iPSC-Derived MSCs

By Leave a Comment

This is an interview with Dr. Paul Wotton, who joined Cynata Therapeutics Board of Directors in June, 2016.  Dr. Wotton was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through an all-cash take-over by Astellas Pharma valued at $379 million.  [Read more…]

Cynata Reports Positive 28-day Data from Cohort B of Phase 1 Trial of CYP-001 in GvHD

By Leave a Comment

MELBOURNE, Australia, June 21, 2018 — Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001, the Company’s lead Cymerus™ mesenchymal stem cell (MSC) product candidate, in steroid-resistant acute graft-versus-host disease (GvHD). [Read more…]

Exciting Early Results in Cynata’s UK Trial of iPSC-Derived MSC Therapeutic Product

By Leave a Comment

 Patients in Cohort A Respond Well, 1st Patient in Cohort B Dosed in Cynata’s CYP-001 Trial

Cynata TherapeuticsAustralian stem cell company, Cynata Therapeutics has released exciting early results from its ongoing clinical trial in the UK utilizing an iPS cell-derived mesenchymal stem cell (MSC) therapeutic product. [Read more…]

BioInformant's World-Class Clients